Home>>Signaling Pathways>> Microbiology & Virology>> Antibiotic>>Pirlimycin
Pirlimycin Catalog No.GC12836

lincosamide antibiotic

Size Price Stock Qty
1mg
$216.00
In stock
5mg
$758.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 79548-73-5 SDF
Synonyms U-57930E
Chemical Name methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-4-ethyl-2-piperidinyl]carbonyl]amino]-1-thio-L-threo-α-D-galacto-octopyranoside
Canonical SMILES CC[C@@H]1CCN[C@H](C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O)C1
Formula C17H31ClN2O5S M.Wt 411.0
Solubility Soluble in ethanol; methanol; DMSO; dimethyl formamide; water Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Pirlimycin, a lincosamide antibiotic, is effective against gram-positive bacteria, including Staphylococcus, Bacteroides, Streptococcus, and Plasmodium. It functions via inhibiting protein synthesis in bacteria by inducing premature dissociation of the peptidyl-tRNA from the ribosome.

In vitro: Pirlimycin showed activity against Helicobacter pylori with a minimal inhibitory concentration [MIC] 50 of 4 μg/ml and an MIC90 of 64 μg/ml [1].

In vivo: Cows were treated with 50 mg of pirlimycin via two intramammary infusions per quarter at a 24- hour interval (2-day) for 2, 5, or 8 days. Pirlimycin showed antibiotic therapy against environmental Streptococcus spp and Staphylococcus aureus intramammary individual and combined infections [1]. Specifically, pirlimycin cured environmental Streptococcus spp infections in 66.7% (14/21), 85% (17/20), 100% (14/14) in the 2-day group, 5-day group and 8-day group, respectively. S. aureus infections were cured by the treatment of pirlimycin in 13.3% (2/15), 31.3% (5/16), 83.3% (5/6) in the 2-day group, 5-day group and 8-day group, respectively. Furthermore, S. aureus, S. dysgalactiae subsp dysgalactiae, and Enterococcus spp intramammary infections were eliminated by the extended treatment of pirlimycin in 8-day group [2].

References:
[1].  Westblom, T., Midkiff, B., & Czinn, S. In vitro susceptibility ofHelicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A). European Journal of Clinical Microbiology & Infectious Diseases. 1993; 12(7): 560-562.
[2].  B. E. Gillespie, H. Moorehead, P. Lunn, H. H. Dowlen, D. L. Johnson, K. C. Lamar, M. J. Lewis, S. J. Ivey, J. W. Hallberg, S. T. Chester, and S. P. Oliver. Efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental Streptococcus spp and Staphylococcus aureus intramammary infections in lactating dairy cows. Veterinary Therapeutics. 2002; 3(4): 373-80.